1 of 3
FEATURED COMPANIES
- Abbott Laboratories
- Allergan, Plc
- C.R. Bard, Inc.
- Medtronic
- Mylan N.V.
- Novartis AG
- MORE
The global drug device combination product market size is expected to reach USD 177.7 billion by 2024, clockingin a 7.9% CAGR during the forecast period. Rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market.
These devices facilitate early diagnosis and reduced treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.
Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.
Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.
Further key findings from the study suggest:
Please note: This product will be delivered within 48 business hours after receipt of order.
These devices facilitate early diagnosis and reduced treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.
Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.
Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.
Further key findings from the study suggest:
- Transdermal patch held the dominant share by product in 2015 owing to increasing demand for self-administration of drugs in diseases requiring long-term treatment
- The inhalers segment is anticipated to exhibit a lucrative CAGR of 9.5% over the forecast period owing to rising prevalence of chronic diseases
- North America held the largest share of over 42.0% in 2015 in terms of region owing to extensive new product development activities conducted by prominent players across this region
- Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to increasing healthcare spending and rising awareness levels of physicians pertaining to benefits of these products
- Key market players are engaged in various strategies such as new product launch and distribution agreements to gain market penetration. For instance, in February 2016, Medtronic introduced the New Resolute Onyx drug-eluting stent, commercially available in different sizes in Europe, thereby enhancing the company’s current product offerings
- High operational cost, stringent regulatory framework, and capital requirement keep entry barriers at a higher level, owing to which, threat of new entrants is expected to be low.
Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Abbott Laboratories
- Allergan, Plc
- C.R. Bard, Inc.
- Medtronic
- Mylan N.V.
- Novartis AG
- MORE
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Market Snapshot
Chapter 4. Market Variables, Trends & Scope
4.1. Market segmentation & scope
4.2. Market Driver Analysis
4.2.1. Increasing demand for minimally invasive drug delivery devices
4.2.2. Technological advancements
4.2.3. Growing popularity of point of care treatment
4.2.4. Consistent interventions by government healthcare organizations
4.2.5. Increasing awareness levels
4.2.6. Improving medical reimbursement framework
4.3. Market Restraint Analysis
4.3.1. High associated costs
4.3.2. Technical challenges in drug delivery
4.4. Penetration & Growth Prospect Mapping
4.5. Drug Device Combination - SWOT Analysis, By Factor (political & legal, economic and technological)
4.6. Industry Analysis - Porter's
Chapter 5. Market Categorization 1: Product Estimates & Trend Analysis
5.1. Drug device combination market: Product Movement Analysis
5.2. Infusion Pumps
5.2.1. Infusion pumps market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.2. Volumetric
5.2.2.1. Volumetric market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.3. Disposable
5.2.3.1. Disposable market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.4. Syringe
5.2.4.1. Syringe market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.5. Ambulatory
5.2.5.1. Ambulatory market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.6. ImplanTable
5.2.6.1. ImplanTable market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.7. Insulin
5.2.7.1. Insulin market estimates and forecasts, 2013 - 2024 (USD Billion)
5.3. Orthopedic Combination Products
5.3.1. Orthopedic combination products market estimates and forecasts, 2013 - 2024 (USD Billion)
5.3.2. Bone graft implants
5.3.2.1. Bone graft implants market estimates and forecasts, 2013 - 2024 (USD Billion)
5.3.3. Antibiotic bone cement
5.3.3.1. Antibiotic bone cement market estimates and forecasts, 2013 - 2024 (USD Billion)
5.4. Photodynamic Therapy Devices
5.4.1. Photodynamic therapy devices market estimates and forecasts, 2013 - 2024 (USD Billion)
5.5. Transdermal Patches
5.5.1. Transdermal patches market estimates and forecasts, 2013 - 2024 (USD Billion)
5.6. Drug Eluting Stents
5.6.1. Drug eluting stents market estimates and forecasts, 2013 - 2024 (USD Billion)
5.6.2. Coronary stents
5.6.2.1. Coronary stents market estimates and forecasts, 2013 - 2024 (USD Billion)
5.6.2.2. Peripheral vascular stents market estimates and forecasts, 2013 - 2024 (USD Billion)
5.7. Wound Care Products
5.7.1. Wound care products market estimates and forecasts, 2013 - 2024 (USD Billion)
5.8. Inhalers
5.8.1. Inhalers market estimates and forecasts, 2013 - 2024 (USD Billion)
5.8.2. Dry powder
5.8.2.1. Dry powder market estimates and forecasts, 2013 - 2024 (USD Billion)
5.8.3. Nebulizers
5.8.3.1. Nebulizers market estimates and forecasts, 2013 - 2024 (USD Billion)
5.8.4. Metered dose
5.8.4.1. Metered dose market estimates and forecasts, 2013 - 2024 (USD Billion)
5.9. Antimicrobial Catheters
5.9.1. Antimicrobial catheters market estimates and forecasts, 2013 - 2024 (USD Billion)
5.9.2. Urological
5.9.2.1. Urological market estimates and forecasts, 2013 - 2024 (USD Billion)
5.9.3. Cardiovascular
5.9.3.1. Cardiovascular market estimates and forecasts, 2013 - 2024 (USD Billion)
5.9.4. Others
5.9.4.1. Others market estimates and forecasts, 2013 - 2024 (USD Billion)
5.10. Others
5.10.1. Others market estimates and forecasts, 2013 - 2024 (USD Billion)
Chapter 6. Market Categorization 4: Regional Estimates & Trend Analysis, By Product, Application & Test
6.1. Drug Device Combination Market Share By Region, 2015 & 2024
6.2. North America
6.2.1. North America market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.2.1.1. U.S. market estimates and forecasts
6.2.1.2. Canada market estimates and forecasts
6.3. Europe
6.3.1. Europe market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.3.1.1. UK market estimates and forecasts
6.3.1.2. Germany market estimates and forecasts
6.4. Asia Pacific
6.4.1. Asia Pacific market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.4.1.1. Japan market estimates and forecasts
6.4.1.2. China market estimates and forecasts
6.4.1.3. India market estimates and forecasts
6.5. Latin America
6.5.1. Latin America market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.5.1.1. Brazil market estimates and forecasts
6.5.1.2. Mexico market estimates and forecasts
6.6. MEA
6.6.1. MEA market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.6.1.1. South Africa market estimates and forecasts
Chapter 7. Competitive Landscape
7.1. Strategy framework
7.2. Market participation categorization
7.3. Company Profiles
7.3.1. Abbott Laboratories
7.3.1.1. Company overview
7.3.1.2. Financial performance
7.3.1.3. Product benchmarking
7.3.1.4. Strategic initiatives
7.3.2. Terumo Corporation
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Stryker Corporation
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. Mylan N.V.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Medtronic
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. St.Jude Medical, Inc.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Allergan, Plc
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Boston Scientific Corporation
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Novartis AG
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Teleflex Incorporated
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. C.R. Bard, Inc.
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. W.L.Core & Associates, Inc.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
List of Tables
Table 1 Country share estimation
Table 2 North America drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 3 U.S. drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 4 Canada drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 5 Europe drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 6 Germany drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 7 UK drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 8 Asia Pacific drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 9 Japan drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 10 China drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 11 India drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 12 Latin America drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 13 Brazil drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 14 Mexico drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 15 MEA drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 16 South Africa drug device combination market, by product, 2013 - 2024 (USD Billion)
List of Figures
FIG. 1 Market summary (USD Billion)
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 8 Porter’s five forces analysis
FIG. 9 Drug device combination market product outlook key takeaways
FIG. 10 Drug device combination market: Product movement analysis
FIG. 11 Global infusion pumps market, 2013 - 2024 (USD Billion)
FIG. 12 Global volumetric market, 2013 - 2024 (USD Billion)
FIG. 13 Global disposable market, 2013 - 2024 (USD Billion)
FIG. 14 Global syringe market, 2013 - 2024 (USD Billion)
FIG. 15 Global ambulatory market, 2013 - 2024 (USD Billion)
FIG. 16 Global implanTable market, 2013 - 2024 (USD Billion)
FIG. 17 Global insulin market, 2013 - 2024 (USD Billion)
FIG. 18 Global orthopedic combination products market, 2013 - 2024 (USD Billion)
FIG. 19 Global bone graft implants market, 2013 - 2024 (USD Billion)
FIG. 20 Global antibiotic bone cement market, 2013 - 2024 (USD Billion)
FIG. 21 Global photodynamic therapy devices market, 2013 - 2024 (USD Billion)
FIG. 22 Global transdermal patches market, 2013 - 2024 (USD Billion)
FIG. 23 Global drug eluting stents market, 2013 - 2024 (USD Billion)
FIG. 24 Global coronary stents market, 2013 - 2024 (USD Billion)
FIG. 25 Global peripheral vascular stents market, 2013 - 2024 (USD Billion)
FIG. 26 Global wound care products market, 2013 - 2024 (USD Billion)
FIG. 27 Global inhalers market, 2013 - 2024 (USD Billion)
FIG. 28 Global dry powder market, 2013 - 2024 (USD Billion)
FIG. 29 Global nebulizers market, 2013 - 2024 (USD Billion)
FIG. 30 Global metered dose market, 2013 - 2024 (USD Billion)
FIG. 31 Global antimicrobial catheters market, 2013 - 2024 (USD Billion)
FIG. 32 Global urological market, 2013 - 2024 (USD Billion)
FIG. 33 Global cardiovascular market, 2013 - 2024 (USD Billion)
FIG. 34 Global others market, 2013 - 2024 (USD Billion)
FIG. 35 Global others market, 2013 - 2024 (USD Billion)
FIG. 36 Regional market place: Key takeaways
FIG. 37 Regional outlook, 2015 & 2024
FIG. 38 North America drug device combination market, 2013 - 2024 (USD Billion)
FIG. 39 U.S. drug device combination market, 2013 - 2024 (USD Billion)
FIG. 40 Canada drug device combination market, 2013 - 2024 (USD Billion)
FIG. 41 Europe drug device combination market, 2013 - 2024 (USD Billion)
FIG. 42 Germany drug device combination market, 2013 - 2024 (USD Billion)
FIG. 43 UK drug device combination market, 2013 - 2024 (USD Billion)
FIG. 44 Asia Pacific drug device combination market, 2013 - 2024 (USD Billion)
FIG. 45 Japan drug device combination market, 2013 - 2024 (USD Billion)
FIG. 46 China drug device combination market, 2013 - 2024 (USD Billion)
FIG. 47 India drug device combination market, 2013 - 2024 (USD Billion)
FIG. 48 Latin America drug device combination market, 2013 - 2024 (USD Billion)
FIG. 49 Brazil drug device combination market, 2013 - 2024 (USD Billion)
FIG. 50 Mexico drug device combination market, 2013 - 2024 (USD Billion)
FIG. 51 MEA drug device combination market, 2013 - 2024 (USD Billion)
FIG. 52 South Africa drug device combination market, 2013 - 2024 (USD Billion)
FIG. 53 Strategy framework
FIG. 54 Participant categorization
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Market Snapshot
Chapter 4. Market Variables, Trends & Scope
4.1. Market segmentation & scope
4.2. Market Driver Analysis
4.2.1. Increasing demand for minimally invasive drug delivery devices
4.2.2. Technological advancements
4.2.3. Growing popularity of point of care treatment
4.2.4. Consistent interventions by government healthcare organizations
4.2.5. Increasing awareness levels
4.2.6. Improving medical reimbursement framework
4.3. Market Restraint Analysis
4.3.1. High associated costs
4.3.2. Technical challenges in drug delivery
4.4. Penetration & Growth Prospect Mapping
4.5. Drug Device Combination - SWOT Analysis, By Factor (political & legal, economic and technological)
4.6. Industry Analysis - Porter's
Chapter 5. Market Categorization 1: Product Estimates & Trend Analysis
5.1. Drug device combination market: Product Movement Analysis
5.2. Infusion Pumps
5.2.1. Infusion pumps market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.2. Volumetric
5.2.2.1. Volumetric market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.3. Disposable
5.2.3.1. Disposable market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.4. Syringe
5.2.4.1. Syringe market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.5. Ambulatory
5.2.5.1. Ambulatory market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.6. ImplanTable
5.2.6.1. ImplanTable market estimates and forecasts, 2013 - 2024 (USD Billion)
5.2.7. Insulin
5.2.7.1. Insulin market estimates and forecasts, 2013 - 2024 (USD Billion)
5.3. Orthopedic Combination Products
5.3.1. Orthopedic combination products market estimates and forecasts, 2013 - 2024 (USD Billion)
5.3.2. Bone graft implants
5.3.2.1. Bone graft implants market estimates and forecasts, 2013 - 2024 (USD Billion)
5.3.3. Antibiotic bone cement
5.3.3.1. Antibiotic bone cement market estimates and forecasts, 2013 - 2024 (USD Billion)
5.4. Photodynamic Therapy Devices
5.4.1. Photodynamic therapy devices market estimates and forecasts, 2013 - 2024 (USD Billion)
5.5. Transdermal Patches
5.5.1. Transdermal patches market estimates and forecasts, 2013 - 2024 (USD Billion)
5.6. Drug Eluting Stents
5.6.1. Drug eluting stents market estimates and forecasts, 2013 - 2024 (USD Billion)
5.6.2. Coronary stents
5.6.2.1. Coronary stents market estimates and forecasts, 2013 - 2024 (USD Billion)
5.6.2.2. Peripheral vascular stents market estimates and forecasts, 2013 - 2024 (USD Billion)
5.7. Wound Care Products
5.7.1. Wound care products market estimates and forecasts, 2013 - 2024 (USD Billion)
5.8. Inhalers
5.8.1. Inhalers market estimates and forecasts, 2013 - 2024 (USD Billion)
5.8.2. Dry powder
5.8.2.1. Dry powder market estimates and forecasts, 2013 - 2024 (USD Billion)
5.8.3. Nebulizers
5.8.3.1. Nebulizers market estimates and forecasts, 2013 - 2024 (USD Billion)
5.8.4. Metered dose
5.8.4.1. Metered dose market estimates and forecasts, 2013 - 2024 (USD Billion)
5.9. Antimicrobial Catheters
5.9.1. Antimicrobial catheters market estimates and forecasts, 2013 - 2024 (USD Billion)
5.9.2. Urological
5.9.2.1. Urological market estimates and forecasts, 2013 - 2024 (USD Billion)
5.9.3. Cardiovascular
5.9.3.1. Cardiovascular market estimates and forecasts, 2013 - 2024 (USD Billion)
5.9.4. Others
5.9.4.1. Others market estimates and forecasts, 2013 - 2024 (USD Billion)
5.10. Others
5.10.1. Others market estimates and forecasts, 2013 - 2024 (USD Billion)
Chapter 6. Market Categorization 4: Regional Estimates & Trend Analysis, By Product, Application & Test
6.1. Drug Device Combination Market Share By Region, 2015 & 2024
6.2. North America
6.2.1. North America market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.2.1.1. U.S. market estimates and forecasts
6.2.1.2. Canada market estimates and forecasts
6.3. Europe
6.3.1. Europe market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.3.1.1. UK market estimates and forecasts
6.3.1.2. Germany market estimates and forecasts
6.4. Asia Pacific
6.4.1. Asia Pacific market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.4.1.1. Japan market estimates and forecasts
6.4.1.2. China market estimates and forecasts
6.4.1.3. India market estimates and forecasts
6.5. Latin America
6.5.1. Latin America market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.5.1.1. Brazil market estimates and forecasts
6.5.1.2. Mexico market estimates and forecasts
6.6. MEA
6.6.1. MEA market estimates and forecasts, by product, 2013 - 2024 (USD Billion)
6.6.1.1. South Africa market estimates and forecasts
Chapter 7. Competitive Landscape
7.1. Strategy framework
7.2. Market participation categorization
7.3. Company Profiles
7.3.1. Abbott Laboratories
7.3.1.1. Company overview
7.3.1.2. Financial performance
7.3.1.3. Product benchmarking
7.3.1.4. Strategic initiatives
7.3.2. Terumo Corporation
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Stryker Corporation
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. Mylan N.V.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Medtronic
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. St.Jude Medical, Inc.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Allergan, Plc
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Boston Scientific Corporation
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Novartis AG
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Teleflex Incorporated
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. C.R. Bard, Inc.
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. W.L.Core & Associates, Inc.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
List of Tables
Table 1 Country share estimation
Table 2 North America drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 3 U.S. drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 4 Canada drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 5 Europe drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 6 Germany drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 7 UK drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 8 Asia Pacific drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 9 Japan drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 10 China drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 11 India drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 12 Latin America drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 13 Brazil drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 14 Mexico drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 15 MEA drug device combination market, by product, 2013 - 2024 (USD Billion)
Table 16 South Africa drug device combination market, by product, 2013 - 2024 (USD Billion)
List of Figures
FIG. 1 Market summary (USD Billion)
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 8 Porter’s five forces analysis
FIG. 9 Drug device combination market product outlook key takeaways
FIG. 10 Drug device combination market: Product movement analysis
FIG. 11 Global infusion pumps market, 2013 - 2024 (USD Billion)
FIG. 12 Global volumetric market, 2013 - 2024 (USD Billion)
FIG. 13 Global disposable market, 2013 - 2024 (USD Billion)
FIG. 14 Global syringe market, 2013 - 2024 (USD Billion)
FIG. 15 Global ambulatory market, 2013 - 2024 (USD Billion)
FIG. 16 Global implanTable market, 2013 - 2024 (USD Billion)
FIG. 17 Global insulin market, 2013 - 2024 (USD Billion)
FIG. 18 Global orthopedic combination products market, 2013 - 2024 (USD Billion)
FIG. 19 Global bone graft implants market, 2013 - 2024 (USD Billion)
FIG. 20 Global antibiotic bone cement market, 2013 - 2024 (USD Billion)
FIG. 21 Global photodynamic therapy devices market, 2013 - 2024 (USD Billion)
FIG. 22 Global transdermal patches market, 2013 - 2024 (USD Billion)
FIG. 23 Global drug eluting stents market, 2013 - 2024 (USD Billion)
FIG. 24 Global coronary stents market, 2013 - 2024 (USD Billion)
FIG. 25 Global peripheral vascular stents market, 2013 - 2024 (USD Billion)
FIG. 26 Global wound care products market, 2013 - 2024 (USD Billion)
FIG. 27 Global inhalers market, 2013 - 2024 (USD Billion)
FIG. 28 Global dry powder market, 2013 - 2024 (USD Billion)
FIG. 29 Global nebulizers market, 2013 - 2024 (USD Billion)
FIG. 30 Global metered dose market, 2013 - 2024 (USD Billion)
FIG. 31 Global antimicrobial catheters market, 2013 - 2024 (USD Billion)
FIG. 32 Global urological market, 2013 - 2024 (USD Billion)
FIG. 33 Global cardiovascular market, 2013 - 2024 (USD Billion)
FIG. 34 Global others market, 2013 - 2024 (USD Billion)
FIG. 35 Global others market, 2013 - 2024 (USD Billion)
FIG. 36 Regional market place: Key takeaways
FIG. 37 Regional outlook, 2015 & 2024
FIG. 38 North America drug device combination market, 2013 - 2024 (USD Billion)
FIG. 39 U.S. drug device combination market, 2013 - 2024 (USD Billion)
FIG. 40 Canada drug device combination market, 2013 - 2024 (USD Billion)
FIG. 41 Europe drug device combination market, 2013 - 2024 (USD Billion)
FIG. 42 Germany drug device combination market, 2013 - 2024 (USD Billion)
FIG. 43 UK drug device combination market, 2013 - 2024 (USD Billion)
FIG. 44 Asia Pacific drug device combination market, 2013 - 2024 (USD Billion)
FIG. 45 Japan drug device combination market, 2013 - 2024 (USD Billion)
FIG. 46 China drug device combination market, 2013 - 2024 (USD Billion)
FIG. 47 India drug device combination market, 2013 - 2024 (USD Billion)
FIG. 48 Latin America drug device combination market, 2013 - 2024 (USD Billion)
FIG. 49 Brazil drug device combination market, 2013 - 2024 (USD Billion)
FIG. 50 Mexico drug device combination market, 2013 - 2024 (USD Billion)
FIG. 51 MEA drug device combination market, 2013 - 2024 (USD Billion)
FIG. 52 South Africa drug device combination market, 2013 - 2024 (USD Billion)
FIG. 53 Strategy framework
FIG. 54 Participant categorization
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Abbott Laboratories
- Terumo Corporation
- Stryker Corporation
- Mylan N.V.
- Medtronic
- St.Jude Medical, Inc.
- Allergan, Plc
- Boston Scientific Corporation
- Novartis AG
- Teleflex Incorporated
- C.R. Bard, Inc.
- W.L.Core & Associates, Inc.
Note: Product cover images may vary from those shown
